Alpha Pro Tech, LTD. Announces Financial Results for the Third Quarter Ended September 30, 2014

Record Quarterly Building Supply Segment Sales of $8.5 Million
Income from Operations Increased 15.6% for the Third Quarter and Increased 32.2% Year to Date

  • Net sales increased 4.1% to $13.2 million for the quarter ended September 30, 2014, compared to $12.7 million for the quarter ended September 30, 2013, and increased 6.4% to $35.4 million for the nine-month period ended September 30, 2014 from $33.3 million for the comparable nine-month period of 2013.

TSO3 in Label Review for its STERIZONE® Sterilization System - Company to submit Final Labeling to US Regulatory Authorities for Sterilizer accessories

QUÉBEC CITY, Oct. 22, 2014 - TSO3 Inc. (TOS.TO) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that after a series of communications with US Regulatory Authorities, the Company has submitted revised labeling for the sterilizer, and is now finalizing labeling for accessory devices such as the Biological and Chemical Indicators used as part of the sterilization system.  Such revisions are required so that all components of the entire system (sterilizer and accessories) can be in final review simultaneously.

Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi

Unilife to be the sole provider of wearable injectors for all of Sanofi's applicable large dose volume drugs

YORK, Pa., Oct. 6, 2014 -- Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Additionally the agreement will allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.

Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference

Toronto, Ontario -- October 16, 2014 / Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds ("PDCs") in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014.

http://theralase.com/wp-content/uploads/2014/10/Biophysical-in-vitro-ex-vivo.pdf

Cancer remains one of the top human conditions and effective minimal or non-invasive treatments with low side effects and high success rates are urgently needed. Photo Dynamic Therapy ("PDT"), the combination of a Photo Dynamic Compound ("PDC") and a specific wavelength of light to produce cytotoxic (cell death) oxygen species, has been shown to be a promising avenue for cancer treatment.

IMRIS neurosurgical HFD rocker arm receives FDA clearance

MINNEAPOLIS, Sept. 11, 2014 - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced a new rocker arm accessory that expands choices for neurosurgeons to select the best fixation suited for patients during procedures using intraoperative imaging inside the VISIUS Surgical Theatre. The accessory recently received 510(k) clearance from the U.S. Food and Drug Administration.

The new rocker arm accessory provides more flexibility for the surgeon to stabilize, support and position patient heads with varying cranial anatomy, sizes and conditions using the MRI-compatible IMRIS HFD. When attached to the head fixation device (HFD) - a clamp-like device - the rocker arm helps to reduce the pressure on the individual contact points on the patient's skull.